Qt Imaging Holdings, INC 8-K filings

QT Imaging Holdings has appointed Dr. Raluca Dinu as Acting CEO and Anastas Budagov as CFO, effective March 12, 2024, marking a significant leadership change.

QT Imaging Holdings has changed the ticker symbol for its warrants to QTIWW and delisted its units following the completion of its business combination.

QT Imaging Holdings, Inc. has granted restricted stock units to participants under its 2024 Equity Incentive Plan, subject to the terms and conditions outlined in the grant notice and agreement.

QT Imaging has announced its first commercial sale of the QTI Breast Acoustic CT system to True Health Center for Functional Medicine, marking a significant milestone in its strategic partnership with NXC Imaging.

QT Imaging Holdings, a medical device company focused on innovative body imaging systems, has finalized its merger with GigCapital5 and will begin trading on NASDAQ under the ticker symbol QTI on March 5, 2024.

GigCapital5 and QT Imaging's business combination is set to finalize on March 4, 2024, with the combined entity, QT Imaging Holdings, commencing trading on Nasdaq under the ticker symbol QTI on March 5, 2024.

GigCapital5, Inc. has entered into amended agreements to finalize its merger with QT Imaging, settling outstanding service fees with the issuance of shares.

GigCapital5 stockholders have approved the business combination with QT Imaging, including the merger and related transactions.

GigCapital5 has extended the deadline for stockholders to exercise redemption rights due to a procedural error by Continental Stock Transfer & Trust Company.

GigCapital5 has announced a non-binding letter of intent with Canon Medical Systems for a potential OEM agreement for QT scanners, following the purchase of two scanners for feasibility studies.

GigCapital5 amended a promissory note with its sponsor, GigAcquisitions5, LLC, increasing the principal amount to $262,246.92 to provide additional working capital.

GigCapital5 and QT Imaging have amended their business combination agreement to revise the calculation of shares issued for excess transaction expenses.